CD19 and acute lymphoblastic leukemia: This might be a consequence of the continued exposure to modified cells, especially in patients with relapsed ALL who have a negative expression of CD19 or a CD19 splice variant lacking exon 2 that is recognized by CAR-T scFv cells [173].